Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Aging
- Health Care Worker Patient Transmission
- Healthy
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 90 years
- Gender
- Both males and females
Description
This is a two-cohort prospective randomized study intended to test the role of Zinc versus multivitamin supplementation in supporting immune health in the setting of the COVID-19 pandemic. Individuals over 50 years old or primary health care professionals over the age of 18 who have had no evidence ...
This is a two-cohort prospective randomized study intended to test the role of Zinc versus multivitamin supplementation in supporting immune health in the setting of the COVID-19 pandemic. Individuals over 50 years old or primary health care professionals over the age of 18 who have had no evidence of prior COVID-19 infection and who have been asymptomatic for 7 days prior to enrollment will be randomized at the individual level to take either PreserVision AREDS formulation soft gels or tablets with 69.6mg/day Zinc supplementation or to receive a multivitamin supplement with 11mg of zinc/day.
Tracking Information
- NCT #
- NCT04551339
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Atta Behfar, MD, PhD Mayo Clinic Principal Investigator: Albert Hakaim, MD Mayo Clinic Principal Investigator: Ayan Sen, MD Mayo Clinic
Get Well Soon